阿基仑赛治疗大B细胞淋巴瘤的生存分析
这项3期试验将早期复发或难治性大B细胞淋巴瘤患者按1:1随机分配接受阿基仑赛(axi-cel)或标准治疗。在中位随访47.2个月时,axi-cel组总生存期显著长于标准治疗组,4年总生存率分别为54.6%和46.0%(HR 0.73,95%CI 0.54-0.98,P=0.03)。
要点
- axi-cel组中位总生存期未达到,标准治疗组为31.1个月。
- 4年总生存率axi-cel组54.6% vs 标准治疗组46.0%(HR 0.73)。
- 中位无进展生存期axi-cel组14.7个月 vs 标准治疗组3.7个月。
核心结论
- 在中位随访47.2个月时,axi-cel作为早期复发或难治性大B细胞淋巴瘤的二线治疗,总生存期显著长于标准治疗。
研究设计与样本
- 3期随机对照试验,将早期复发或难治性大B细胞淋巴瘤患者按1:1比例随机分配接受axi-cel或标准治疗(2至3个周期化学免疫治疗后,对有效患者进行大剂量化疗联合自体干细胞移植)。
- 共359例患者接受随机分配,axi-cel组180例,标准治疗组179例。
- 主要终点为无事件生存期,关键次要终点为缓解和总生存期;本文报告首例患者随机化后5年时的预设总生存期分析结果。
主要发现
- 在中位随访47.2个月时,axi-cel组报告死亡82例,标准治疗组报告死亡95例。
- axi-cel组中位总生存期未达到,标准治疗组为31.1个月;估计4年总生存率分别为54.6%和46.0%(死亡风险比0.73;95%CI 0.54至0.98;分层双侧对数秩检验P=0.03)。
- 在意向治疗人群中观察到axi-cel带来的生存获益,该人群包括74%的原发性难治性疾病及其他高危特征患者。
- 研究者评估的中位无进展生存期在axi-cel组为14.7个月,标准治疗组为3.7个月,估计4年百分比分别为41.8%和24.4%(风险比0.51;95%CI 0.38至0.67)。
- 自无事件生存期主要分析以来,未发生新的治疗相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those who received standard care. Data were needed on longer-term outcomes. METHODS: In this trial, we randomly assigned patients with early relapsed or refractory large B-cell lymphoma in a 1:1 ratio to receive either axi-cel or standard care (two to three cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem-cell transplantation in patients who had a response). The primary outcome was event-free survival, and key secondary outcomes were response and overall survival. Here, we report the results of the prespecified overall survival analysis at 5 years after the first patient underwent randomization. RESULTS: A total of 359 patients underwent randomization to receive axi-cel (180 patients) or standard care (179 patients). At a median follow-up of 47.2 months, death had been reported in 82 patients in the axi-cel group and in 95 patients in the standard-care group. The median overall survival was not reached in the axi-cel group and was 31.1 months in the standard-care group; the estimated 4-year overall survival was 54.6% and 46.0%, respectively (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.54 to 0.98; P = 0.03 by stratified two-sided log-rank test). This increased survival with axi-cel was observed in the intention-to-treat population, which included 74% of patients with primary refractory disease and other high-risk features. The median investigator-assessed progression-free survival was 14.7 months in the axi-cel group and 3.7 months in the standard-care group, with estimated 4-year percentages of 41.8% and 24.4%, respectively (hazard ratio, 0.51; 95% CI, 0.38 to 0.67). No new treatment-related deaths had occurred since the primary analysis of event-free survival. CONCLUSIONS: At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall survival than standard care. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).
引用
- Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023. PMID: 37272527. doi:10.1056/NEJMoa2301665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。